<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi> 1 (GLP-1) and gastric inhibitory <z:chebi fb="1" ids="15841">polypeptide</z:chebi> (GIP) are important factors in the pathogenesis of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and have a promising therapeutic potential </plain></SENT>
<SENT sid="1" pm="."><plain>Alterations of their secretion, in vivo degradation, and elimination in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> (CRI) have not yet been characterized </plain></SENT>
<SENT sid="2" pm="."><plain>Ten patients with CRI (aged 47 +/- 15 years, BMI 24.5 +/- 2.2 kg/m(2), and serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> 2.18 +/- 0.86 mg/dl) and 10 matched healthy control subjects (aged 44 +/- 12 years, BMI 24.9 +/- 3.4 kg/m(2), and serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> 0.89 +/- 0.10 mg/dl) were included </plain></SENT>
<SENT sid="3" pm="."><plain>On separate occasions, an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test (75 g), an intravenous infusion of GLP-1 (0.5 pmol </plain></SENT>
<SENT sid="4" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="5" pm="."><plain>min(-1) over 30 min), and an intravenous infusion of GIP (1.0 pmol </plain></SENT>
<SENT sid="6" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="7" pm="."><plain>min(-1) over 30 min) were performed </plain></SENT>
<SENT sid="8" pm="."><plain>Venous blood samples were drawn for the determination of <z:chebi fb="105" ids="17234">glucose</z:chebi> (<z:chebi fb="105" ids="17234">glucose</z:chebi> oxidase), insulin, C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, GLP-1 (total and intact), and GIP (total and intact; specific immunoassays) </plain></SENT>
<SENT sid="9" pm="."><plain>Plasma levels of GIP (3-42) and GLP-1 (9-36 amide) were calculated </plain></SENT>
<SENT sid="10" pm="."><plain>Statistics were performed using repeated-measures and one-way ANOVA </plain></SENT>
<SENT sid="11" pm="."><plain>After the oral <z:chebi fb="105" ids="17234">glucose</z:chebi> load, plasma concentrations of intact GLP-1 and intact GIP reached similar levels in both groups (P = 0.31 and P = 0.87, respectively) </plain></SENT>
<SENT sid="12" pm="."><plain>The concentrations of GIP (3-42) and GLP-1 (9-36 amide) were significantly higher in the patients than in the control subjects (P = 0.0021 and P = 0.027, respectively) </plain></SENT>
<SENT sid="13" pm="."><plain>During and after the exogenous infusion, GLP-1 (9-36 amide) and GIP (3-42) reached higher plasma concentrations in the CRI patients than in the control subjects (P &lt; 0.001 and P = 0.0033, respectively), whereas the plasma levels of intact GLP-1 and GIP were not different between the groups (P = 0.29 and P = 0.27, respectively) </plain></SENT>
<SENT sid="14" pm="."><plain>Plasma half-lives were 3.4 +/- 0.6 and 2.3 +/- 0.4 min for intact GLP-1 (P = 0.13) and 5.3 +/- 0.8 and 3.3 +/- 0.4 min for the GLP-1 metabolite (P = 0.029) for CRI patients vs. healthy control subjects, respectively </plain></SENT>
<SENT sid="15" pm="."><plain>Plasma half-lives of intact GIP were 6.9 +/- 1.4 and 5.0 +/- 1.2 min (P = 0.31) and 38.1 +/- 6.0 and 22.4 +/- 3.0 min for the GIP metabolite (P = 0.032) for CRI patients vs. healthy control subjects, respectively </plain></SENT>
<SENT sid="16" pm="."><plain>Insulin concentrations tended to be lower in the patients during <z:hpo ids='HP_0000001'>all</z:hpo> experiments, whereas C-<z:chebi fb="7" ids="16670">peptide</z:chebi> levels tended to be elevated </plain></SENT>
<SENT sid="17" pm="."><plain>These data underline the importance of the kidneys for the final elimination of GIP and GLP-1 </plain></SENT>
<SENT sid="18" pm="."><plain>The initial dipeptidyl peptidase IV-mediated degradation of both hormones is almost unaffected by impairments in renal function </plain></SENT>
<SENT sid="19" pm="."><plain>Delayed elimination of GLP-1 and GIP in <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> may influence the pharmacokinetics and pharmacodynamics of dipeptidyl peptidase IV-resistant incretin derivatives to be used for the treatment of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>